Delcath Systems to Present at Renshaw 11th Annual Healthcare Conference
NEW YORK, Sept. 4 -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical device company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that its President and CEO Eamonn P. Hobbs will make a presentation to investors at the Rodman & Renshaw 11th Annual Healthcare Conference on Friday, September 11 at 9:10 a.m. Eastern Time in New York. Mr. Hobbs will review the Company's business strategy and historic financial results. A live webcast of the presentation will be available in the investors section of the Company's web site at www.delcath.com. The webcast also will be archived and accessible for ninety days.
Delcath Systems, Inc.
Delcath Systems, Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.